http://www.brodskysmith.com/cases/caesars-entertainment-corp-nasdaq-czr/
Interesting case regarding current shareholders
Interesting case regarding current shareholders
Not interesting at all. If you knew anything about this, you would know it's an ambulance chasing lawsuit. These types of lawsuits are filed by these scumbag outfits looking to make money. Gotta laugh that they say CZR was trading at $16.89 LMAO go find out when that was, it wasn't in the last year. Just goes to show how clueless it is.
Any company that is merging or a buyout is occurring has these types of false lawsuits.
For those that listened and followed along congrats we once again rang the register. For the naysayers, what can I say, you were wrong again...…………… #CRUSH
Any company that is merging or a buyout is occurring has these types of false lawsuits.
For those that listened and followed along congrats we once again rang the register. For the naysayers, what can I say, you were wrong again...…………… #CRUSH
This is a stock that I think has great potential. The company is called Ziopharm Oncology. I currently own 5500 shares at a $4 cost average. I have messaged Ricboff several times about its stock chart so if he reads this, he might give his expert advise.
They are currently in a phase 2 study with Dr. Rosenberg and the National Cancer Institute targeting solid tumors with their sleeping beauty. The company believes that their TCR sleeping beauty can cure 80% of all cancers, and I am banking that they are right. We should start seeing early results in the next 2 months as the first patients are being enrolled now. They also have several other pipelines in the works and they also formed a joint venture in China. One of their biggest financial backers is Michael Dell of Dell computers.
This stock is heavily shorted with about 50 million shorted shares. If this company succeeds and I believe they will, we could see an epic short squeeze.
Here are a few links below if anyone wants to do some research. I can try and answer any questions as well.
https://ir.ziopharm.com/news-releas...-reports-third-quarter-2019-financial-results
https://ziopharm.com/pipeline/
If you have time, watch these videos. I think they are really good.
https://ziopharm.com/news-publications/videos/
Lake Street Capital report
Catalyst-Heavy 18 Months on the Horizon. Affirm BUY Rating And $7 Price Target.
ZIOP announced 3Q19 results and provided updates on its clinical development programs yesterday after market close. Overall, the Company continues to execute against its milestones and we anticipate multiple catalysts in the coming 18 months. Affirming our BUY rating and $7 price target.
CLINICAL DEVELOPMENT UPDATES
The Company provided updates across all three development programs:
TCR Program
1. NCI Phase 2 study: First patient is expected to be treated imminently. 2.
2. MD Anderson collaboration: Two studies are being planned: hotspot mutations and patient-specific neoantigens. Timing guidance for IND submissions and study initiations will be available early 2020.
CAR-T Program
1. Autologous: US clinical hold remains in place. We look forward to updates on Eden BioCell’s (JV partner) progress in China next year.
2. Allogeneic: Company announced on October 1 FDA IND clearance and clinical study could be open as soon as year-end.
IL-12 Program
1. Monotherapy: Interim data to be presented at the Society for NeuroOncology (SNO) meeting in November.
2. Nivolumab combination: Interim data also to be presented at SNO. All 12 patients in the highest-dose level expansion have been enrolled.
3. Cemiplimab combination: The first cohort of 6 patients are enrolled and being monitored. Enrollment is expected to continue near-term.
INVESTMENT THESIS AND VALUATION
Ziopharm is an emerging company in the field of immuno-oncology. By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy. With critical catalysts on the nearterm horizon across its three programs, we see an opportunity for significant value generation. We arrive at our $7 price target using two inputs: (i) the discounted future revenue forecast for Ad-RTS-hIL-12 plus veledimex ($1/share) and (ii) a precedent transaction analysis of two companies that also have T-cell therapy programs ($6/share).
Ok. With respect to this, it is definitely a long shot. Phase II clinical trials are simply not predictable from successes in Phase I trials. Apples and oranges. I looked at their website and saw that they are just at the beginning of clinical trials (which can take several years) and have funding only to carry them three the next 2 years, which is why the shorts are piling on.
https://ir.ziopharm.com/news-releas...presentation-jefferies-2019-london-healthcare
I think the smart (but effortful) way to play this is to actually wait until after the initial short squeeze. This will only happen if the drug shows some signs of working. And if it works then it is a much bigger deal than most drugs. At this moment there is no evidence at all that it works in humans. And it looks to me that it will take another year before any reliable phase II trial results will be announced.
In other words, I don’t think there is any rush at all to move on this even if it works out. Also, with such a big short, the positions will not all move at once. There will be a lot of unreliable news coming out over the next 9 months so it will definitely be a roller coaster ride. My best guess is that if you buy this at a price less than $7.50/share then it will likely go to zero. However if ever breaks $8/share then I’d become interested in it.
Rationale: Seems like an all-or-nothing drug. It either cures 80% of all cancers in which case there’ll be at least 10 years of increasing stock prices, or it will be a dead end or something marginal. No need to rush. Btw, I’m fascinated by that $7 price target after 18 months. It makes my point about there not being a rush on this. Obviously, if there is any evidence the drug works then the price will increase by at least 10 fold (above $50). So what does $7 mean? It means that 18 months from now, we will still not know if the drug works.
Recommendation: The company seems to put out a lot of communications and press releases. I’d follow them and track the stock price’s response to them over the next 6 months. Try to get a feel for what the smart money is doing.
https://ir.ziopharm.com/news-releas...presentation-jefferies-2019-london-healthcare
I think the smart (but effortful) way to play this is to actually wait until after the initial short squeeze. This will only happen if the drug shows some signs of working. And if it works then it is a much bigger deal than most drugs. At this moment there is no evidence at all that it works in humans. And it looks to me that it will take another year before any reliable phase II trial results will be announced.
In other words, I don’t think there is any rush at all to move on this even if it works out. Also, with such a big short, the positions will not all move at once. There will be a lot of unreliable news coming out over the next 9 months so it will definitely be a roller coaster ride. My best guess is that if you buy this at a price less than $7.50/share then it will likely go to zero. However if ever breaks $8/share then I’d become interested in it.
Rationale: Seems like an all-or-nothing drug. It either cures 80% of all cancers in which case there’ll be at least 10 years of increasing stock prices, or it will be a dead end or something marginal. No need to rush. Btw, I’m fascinated by that $7 price target after 18 months. It makes my point about there not being a rush on this. Obviously, if there is any evidence the drug works then the price will increase by at least 10 fold (above $50). So what does $7 mean? It means that 18 months from now, we will still not know if the drug works.
Recommendation: The company seems to put out a lot of communications and press releases. I’d follow them and track the stock price’s response to them over the next 6 months. Try to get a feel for what the smart money is doing.
Hamilbet, I can't argue with anything you said. Great observation and probably the smartest thing to do.
Ziop is funded until 1st quarter 2021.
I really believe the TCR with sleeping beauty is going to show positive results. I know Ziop pays the NCI to do the trials but I can't see why Dr. Rosenberg would choose to do the trial if he didn't think TCR SB works. His right hand man, Drew Deniger also quit the NCI to come and work for ZIOP.
I also think the IL-12 with Veledimex has a chance for a partnership or buyout with a big pharma company. IL-12 is used to treat inoperable brain cancer. 31 patients were treated with a median survival rate of 17.8 months.
https://ir.ziopharm.com/news-releas...nnounces-publication-positive-results-phase-1
I hope I make a nice profit on this investment but I really hope they found a way to cure cancer.
Ziop is funded until 1st quarter 2021.
I really believe the TCR with sleeping beauty is going to show positive results. I know Ziop pays the NCI to do the trials but I can't see why Dr. Rosenberg would choose to do the trial if he didn't think TCR SB works. His right hand man, Drew Deniger also quit the NCI to come and work for ZIOP.
I also think the IL-12 with Veledimex has a chance for a partnership or buyout with a big pharma company. IL-12 is used to treat inoperable brain cancer. 31 patients were treated with a median survival rate of 17.8 months.
https://ir.ziopharm.com/news-releas...nnounces-publication-positive-results-phase-1
I hope I make a nice profit on this investment but I really hope they found a way to cure cancer.
bullets, my 2 cents from a chart standpoint
crazy volatile stock , its price has gone up 4X from Jan to a late-July high then proceeded to drop 40%. Not for the faint at heart, and according to bullets and Hamilbet it'll be feast or famine
3 yr weekly
looking like it wants to form a swing low, at a level where's there strong support. Keep in mind as the other posters noted its heavily shorted, BUT it appears they cant break this level. Its imperative it holds.This is a massive level , its even a heavy volume-at-price level; a lot of action happens at this level. Would not touch this with a 10-foot pole if it breaks this level. Be very careful with 'averaging down' if it breaks (esp., given the info bullets/hamilbet provided) as it could easily drop another 23%
DIOP/XBI (the sector its in) on a regression channel since May has diop underperformng, badly .
6 month daily
200 sma
she will break to either direction. For a trader, adn a couragous one at that-- limit-buy order at $4.55, (adn a stop placed immediately at $3.90ish, or at worse $3.70) A close above $4.55 means it re-claims its 200 sma which would be very very good. If it does she can run to $5.50
bullets, gl
crazy volatile stock , its price has gone up 4X from Jan to a late-July high then proceeded to drop 40%. Not for the faint at heart, and according to bullets and Hamilbet it'll be feast or famine
3 yr weekly
looking like it wants to form a swing low, at a level where's there strong support. Keep in mind as the other posters noted its heavily shorted, BUT it appears they cant break this level. Its imperative it holds.This is a massive level , its even a heavy volume-at-price level; a lot of action happens at this level. Would not touch this with a 10-foot pole if it breaks this level. Be very careful with 'averaging down' if it breaks (esp., given the info bullets/hamilbet provided) as it could easily drop another 23%
DIOP/XBI (the sector its in) on a regression channel since May has diop underperformng, badly .
6 month daily
200 sma
she will break to either direction. For a trader, adn a couragous one at that-- limit-buy order at $4.55, (adn a stop placed immediately at $3.90ish, or at worse $3.70) A close above $4.55 means it re-claims its 200 sma which would be very very good. If it does she can run to $5.50
bullets, gl
In all fairness, this thread was started by me with a history of providing guidance that has made people a lot of money. At least those that listened.
This topic isn't meant for other people to post stock tips under my thread umbrella.
If you want to post some off the wall stock, start your own fucking thread and don't piggy back off my successful thread.
Not being a dick, but I take this serious as not only do I have a lot of money at risk, others have put their money at risk on my recommendation and the work I put into it and the follow up with it.
Leave your BS out of here.
I'll ask to have this locked if need be.
To those that made tons of cash with CZR congrats, another highly successful big ROI and $$$$ return.
This topic isn't meant for other people to post stock tips under my thread umbrella.
If you want to post some off the wall stock, start your own fucking thread and don't piggy back off my successful thread.
Not being a dick, but I take this serious as not only do I have a lot of money at risk, others have put their money at risk on my recommendation and the work I put into it and the follow up with it.
Leave your BS out of here.
I'll ask to have this locked if need be.
To those that made tons of cash with CZR congrats, another highly successful big ROI and $$$$ return.
